Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Innovent Biologics Inc.

www.innoventbio.com/en/

Latest From Innovent Biologics Inc.

New China Approvals Include Amgen, Sanofi, Hengrui Drugs, Innovent Biosimilar

Several high-profile products including Dupixent gain approvals in China.

China Approvals

New China Law Cracks Down On Fake Academic Promotion

Latest regulation aiming to rein in medical sales indicated new round of regulatory tightening in China as pharma firms resume post-coronavirus commercial operations.

China Legislation

New Approvals, Biosecurity In Spotlight As China Gears For National Congress

China grants new approvals to multiple new drugs for cancer and rare diseases, as the government gears up to hold its delayed annual congress in Beijing, attended by thousands of delegates who will vote on key new biosecurity legislation as the pandemic appears to be receding in the country.

Approvals China

Regulatory Blessings Helping China CAR-Ts March Closer To Global Cancer Patients?

A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.

China Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Immune Disorders
  • Metabolic Disorders
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Innovent Biologics Inc.
  • Senior Management
  • Michael Yu, PhD, Pres. & CEO
    Ronald Ede, CFO
    Qinwei Zhou, PhD, COO
    Blake Salisbury, VP, Bus. Dev.
    Min Liu, Chief Commercial Officer
  • Contact Info
  • Innovent Biologics Inc.
    Phone: 512 69566088
    168 Dongping St., Suzhou Industrial Park
    Suzhou, 215123
    China
UsernamePublicRestriction

Register